

Patent Office of the People's Republic of China Grants Sixth Wave Innovations Inc. MIPS Patent for Extraction and Purification of Gold, Mercury, and Scandium

written by Raj Shah | May 5, 2022

May 5, 2022 ([Source](#)) – **Sixth Wave Innovations Inc. (CSE: SIXW) (OTCQB: SIXWF) (FSE: AHUH)** (“Sixth Wave”, “SIXW” or the “**Company**”), a world leader in molecular imprinting technology, announced today that the Patent Office of the People's Republic of China has granted the Company a patent for its unique method of metal extraction and purification using molecularly imprinted polymers. (“**MIPS**”).

This patent extends the Company's existing patent portfolio to include methodologies relating to the molecularly imprinted polymers, which selectively bind to target metals ions, achieving more efficient metal extraction. “Sixth Wave continues to position itself as a leader in technology innovation that allows cleaner and more environmentally friendly exploitation of natural resources. China remains a dominant supplier of critical and precious metals and we are delighted to have been issued this patent in such an important jurisdiction,” said Dr. Gluckman, President and CEO of Sixth Wave.

Sixth Wave believes there are significant opportunities to monetize the Company's metals purification MIPS being sold under the IXOS® brand name. This technology enables the delivery of

efficient, scalable, environmentally friendly, and lower cost solutions to our mining customers.

About Sixth Wave

Sixth Wave is a development stage nanotechnology company with patented technologies that focus on extraction and detection of target substances at the molecular level using highly specialized molecularly imprinted polymers (MIPs). The Company is in the process of commercializing its Affinity™ cannabinoid purification system, as well as, IXOS®, a line of extraction polymers for the gold mining industry.

Sixth Wave can design, develop and commercialize MIP solutions across a broad spectrum of industries. The company is focused on nanotechnology architectures that are highly relevant for detection and separation of viruses, biogenic amines and other pathogens, for which the Company has products at various stages of development.

For more information about Sixth Wave, please visit: www.sixthwave.com.

ON BEHALF OF THE BOARD OF DIRECTORS

“Jon Gluckman”

Jonathan Gluckman, Ph.D., President & CEO

For information, please contact the Company:

Phone: (801) 582-0559

E-mail: info@sixthwave.com

Cautionary Notes

This press release includes certain statements that may be deemed “forward-looking statements” including statements regarding the planned features of the MIPs technology. All

statements in this release, other than statements of historical facts, that address future events or developments that the Company expects, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual events or developments may differ materially from those in forward-looking statements. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause the Company's actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. In particular, successful development and commercialization of the MIPs technology are subject the risk that the MIPs technology may not prove to be successful in detecting virus targets effectively or at all, uncertainty of medical product development, uncertainty of timing or availability of required regulatory approvals, lack of track record of developing products for medical applications and the need for additional capital to carry out product development activities. The value of any products ultimately developed could be negatively impacted if its patent application is not successful. The Company has not yet completed development of a prototype for the product that is subject of its patent application and has not yet applied for regulatory approval for the use of this product from any regulatory agency.